Ingeborg Landerer

Overview
Related items

About Ingeborg Landerer:

No description specified

SEEK ID: https://ldh.zks-freiburg.imise.uni-leipzig.de/people/6

Location: Germany

ORCID: Not specified

Joined: 28th Jul 2025

Expertise: Not specified

Tools: Not specified

help

Their tags

This person has not yet tagged anything.

Related items

Advanced Projects list for this Person with search and filtering

Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus

Programme: This Project is not associated with a Programme

Public web page: Not specified

Start date: 9th Feb 2016

End date: 28th Nov 2023

Untersuchungen zur Prognoseabschätzung der perforierenden Keratoplastikmittels funktionellem Matching von HLA und Minor Antigenen

Programme: This Project is not associated with a Programme

Public web page: Not specified

Treatment of Optic Neuritis with Erythropoietin: a randomised, double-blind, placebo-controlled trial

Programme: This Project is not associated with a Programme

Public web page: Not specified

Eine bizentrische prospektive Phase I/II Studie zur Etablierung von Sicherheit, Verträglichkeit und zur Erfassung erster Daten zur Wirksamkeit von Losartan bei Kindern mit rezessiv dystropher Epidermolysis bullosa

Programme: This Project is not associated with a Programme

Public web page: Not specified

Prospektive, randomisierte, multizentrische Phase II Studie mit niedrig-dosiertem Decitabine (DAC) alleine oder in Kombination mit dem Histon- Deacetylase Inhibitor Valproat (VPA) und All-Transretinsäure (ATRA) bei Patienten über 60 Jahre mit akuter myeloischer Leukämie, bei denen eine Standard-Induktions-Chemotherapie nicht geeignet ist.

Programme: This Project is not associated with a Programme

Public web page: Not specified

Advanced Institutions list for this Person with search and filtering

Zentrum Klinische Studien

ROR ID: Not specified

Department: Not specified

Country: Germany

City: 79110 Freiburg

Web page: https://www.uniklinik-freiburg.de/zks.html

Advanced Publications list for this Person with search and filtering

Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study.

TONE

Abstract (Expand)

BACKGROUND: The human cytokine erythropoietin conveys neuroprotection in animal models but has shown ambiguous results in phase 2 clinical trials in patients with optic neuritis. We assessed the safety … and efficacy of erythropoietin in patients with optic neuritis as a clinically isolated syndrome in a multicentre, prospective, randomised clinical trial. METHODS: This randomised, placebo-controlled, double-blind phase 3 trial, conducted at 12 tertiary referral centres in Germany, included participants aged 18-50 years, within 10 days of onset of unilateral optic neuritis, with visual acuity of 0.5 or less, and without a previous diagnosis of multiple sclerosis. Participants were randomly assigned (1:1) to receive either 33 000 IU erythropoietin or placebo intravenously for 3 days as an adjunct to high-dose intravenous methylprednisolone (1000 mg per day). Block randomisation was performed by the trial statistician using an SAS code that generated randomly varying block sizes, stratified by study site and distributed using sealed envelopes. All trial participants and all study staff were masked to treatment assignment, except the trial pharmacist. The first primary outcome was atrophy of the peripapillary retinal nerve fibre layer (pRNFL), measured by optic coherence tomography (OCT) as the difference in pRNFL thickness between the affected eye at week 26 and the unaffected eye at baseline. The second primary outcome was low contrast letter acuity at week 26, measured as the 2.5% Sloan chart score of the affected eye. Analysis was performed in the full analysis set of all randomised participants for whom treatment was started and at least one follow-up OCT measurement was available. Safety was analysed in all patients who received at least one dose of the trial medication. This trial is registered at ClinicalTrials.gov, NCT01962571. FINDINGS: 108 participants were enrolled between Nov 25, 2014, and Oct 9, 2017, of whom 55 were assigned to erythropoietin and 53 to placebo. Five patients were excluded from the primary analysis due to not receiving the allocated medication, withdrawn consent, revised diagnosis, or loss to follow-up, yielding a full analysis set of 52 patients in the erythropoietin group and 51 in the placebo group. Mean pRNFL atrophy was 15.93 mum (SD 14.91) in the erythropoietin group and 14.65 mum (15.60) in the placebo group (adjusted mean treatment difference 1.02 mum; 95% CI -5.51 to 7.55; p=0.76). Mean low contrast letter acuity scores were 49.60 (21.31) in the erythropoietin group and 49.06 (21.93) in the placebo group (adjusted mean treatment difference -4.03; -13.06 to 5.01). Adverse events occurred in 43 (81%) participants in the erythropoietin group and in 42 (81%) in the placebo group. The most common adverse event was headache, occuring in 15 (28%) patients in the erythropoietin group and 13 (25%) patients in the placebo group. Serious adverse events occurred in eight (15%) participants in the erythropoietin and in four (8%) in the placebo group. One patient (2%) in the erythropoietin group developed a venous sinus thrombosis, which was treated with anticoagulants and resolved without sequelae. INTERPRETATION: Erythropoietin as an adjunct to corticosteroids conveyed neither functional nor structural neuroprotection in the visual pathways after optic neuritis. Future research could focus on modified erythropoietin administration, assess its efficacy independent of corticosteroids, and investigate whether it affects the conversion of optic neuritis to multiple sclerosis. FUNDING: German Federal Ministry of Education and Research (BMBF).

Authors: W. A. Lagreze, S. Kuchlin, G. Ihorst, B. Grotejohann, F. Beisse, M. Volkmann, S. P. Heinrich, P. Albrecht, J. Ungewiss, M. Worner, M. J. Hug, S. Wolf, R. Diem

Date Published: 21st Nov 2021

Publication Type: Journal

PubMed ID: 34800417

Citation: Lancet Neurol. 2021 Dec;20(12):991-1000. doi: 10.1016/S1474-4422(21)00322-7.

Created: 4th Aug 2025 at 10:01

Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 x 2, Phase II Trial.

DECIDER

Abstract (Expand)

PURPOSE: DNA-hypomethylating agents are studied in combination with other epigenetic drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in myeloid neoplasias. A …

Authors: M. Lubbert, O. Grishina, C. Schmoor, R. F. Schlenk, E. Jost, M. Crysandt, M. Heuser, F. Thol, H. R. Salih, M. M. Schittenhelm, U. Germing, A. Kuendgen, K. S. Gotze, H. W. Lindemann, C. Muller-Tidow, G. Heil, S. Scholl, G. Bug, C. Schwaenen, A. Giagounidis, A. Neubauer, J. Krauter, W. Brugger, M. De Wit, R. Wasch, H. Becker, A. M. May, J. Duyster, K. Dohner, A. Ganser, B. Hackanson, H. Dohner

Date Published: 20th Jan 2020

Publication Type: Journal

PubMed ID: 31794324

Citation: J Clin Oncol. 2020 Jan 20;38(3):257-270. doi: 10.1200/JCO.19.01053. Epub 2019 Dec 3.

Created: 4th Aug 2025 at 10:13

Rejection Prophylaxis in Corneal Transplant.

FANCY

Abstract (Expand)

BACKGROUND: Graft rejection. Twenty to thirty percent of patients with corneal transplants experience at least one rejection episode in the first 5 years after transplantation. Prophylaxis through …

Authors: D. Bohringer, B. Grotejohann, G. Ihorst, H. Reinshagen, E. Spierings, T. Reinhard

Date Published: 13th Apr 2018

Publication Type: Journal

PubMed ID: 29735006

Citation: Dtsch Arztebl Int. 2018 Apr 13;115(15):259-265. doi: 10.3238/arztebl.2018.0259.

Created: 4th Aug 2025 at 10:05

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).

ESOPEC

Abstract (Expand)

BACKGROUND: Recent randomized controlled trials comparing neoadjuvant chemoradiation plus surgery or perioperative chemotherapy plus surgery with surgery alone showed significant survival benefits for …

Authors: J. Hoeppner, F. Lordick, T. Brunner, T. Glatz, P. Bronsert, N. Rothling, C. Schmoor, D. Lorenz, C. Ell, U. T. Hopt, J. R. Siewert

Date Published: 19th Jul 2016

Publication Type: Journal

PubMed ID: 27435280

Citation: BMC Cancer. 2016 Jul 19;16:503. doi: 10.1186/s12885-016-2564-y.

Created: 4th Aug 2025 at 10:18

Advanced Documents list for this Person with search and filtering

1 hidden item

(v.1.17.3)

(LDH: v0.3.4)

About NFDI4Health | About Local Data Hub ZKS Freiburg | Partners and Funding | Credits | Terms & Conditions | Privacy Policy | Imprint | Contact us

Copyright © 2008 - 2023 The University of Manchester and HITS gGmbH
Additions copyright ...